COMPANY PROFILE

Orchard Therapeutics

Explore full profile

Hematopoietic stem cell gene therapies for rare diseases

London, United KingdomFounded 2015Biotech & Life Sciences

Valuation $303M Market cap · 2024

Revenue $20M Latest reported FY

Total funding $100–500M Disclosed equity funding

About Orchard Therapeutics

Orchard Therapeutics, a subsidiary of Kyowa Kirin, is a global pharmaceutical company developing and commercializing potentially curative, one-time gene therapies for patients with severe and life-threatening rare diseases. The company was founded in 2015 as a spin-out from University College London (UCL), based on the research of scientific founders Professors Bobby Gaspar and Adrian Thrasher at the UCL Great Ormond Street Institute of Child Health. Dr. Gaspar, who now serves as CEO, was motivated by his work as a pediatric immunologist, seeking a safer and more effective alternative to bone marrow transplants for children with severe immune deficiencies. This led to pioneering the use of a patient's own genetically modified hematopoietic stem cells (HSCs) to correct the underlying cause of a disease.

Read full description

The company's approach involves extracting a patient's blood stem cells, modifying them genetically outside the body (ex vivo) to insert a functional copy of a faulty gene, and then reinfusing them into the patient. This autologous method aims to provide a single, transformative treatment. Orchard's business model centers on the development and commercialization of these high-value therapies. Revenue is generated from the sale of its approved products. In January 2024, Orchard was acquired by Kyowa Kirin, a Japan-based global specialty pharmaceutical company, for approximately $477.6 million, to enhance Kyowa Kirin's pipeline and focus on rare diseases.

Orchard's leading product, marketed as Libmeldy® in Europe and Lenmeldy™ in the U.S., is an approved treatment for early-onset metachromatic leukodystrophy (MLD), a rare and fatal metabolic disorder. Libmeldy received approval from the European Medicines Agency (EMA) in 2020 and the U.S. Food and Drug Administration (FDA) in 2024. The company's clinical-stage pipeline includes therapies for other rare genetic disorders, such as OTL-203 for mucopolysaccharidosis type I Hurler's syndrome (MPS-IH) and OTL-201 for mucopolysaccharidosis type IIIA (MPS-IIIA). The company has also advanced programs for Wiskott-Aldrich syndrome (WAS) and adenosine deaminase severe combined immunodeficiency (ADA-SCID).

Source: Dealroom company data